Digitally delivered interdisciplinary care (ADCompanion) is noninferior to routine care in reducing disease severity in patients with atopic dermatitis
This protocol describes a multicenter randomized noninferiority trial comparing a digital interdisciplinary care concept (ADCompanion) to routine care for atopic dermatitis. The primary endpoint is physician-assessed disease severity (SCORAD) at 6 months, with 603 participants recruited across 7 centers in Germany. Final results are expected in 2026, and the claim of noninferiority is not yet established.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Digitally delivered interdisciplinary care (ADCompanion) is noninferior to routine care in reducing disease severity in patients with atopic dermatitis The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Digitally delivered interdisciplinary care (ADCompanion) is noninferior to routine care in reducing disease severity in patients with atopic dermatitis
This conclusion is most relevant to: Patients with atopic dermatitis (all ages, stratified by age and severity) recruited from 7 centers in Germany.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Remote Interdisciplinary Care for Atopic Dermatitis Using a Digital Care Concept (ADCompanion): Protocol for a Multicenter Randomized Trial. (JMIR research protocols, 2026) —
How It Works
The proposed biological pathway:
- ▸Digital platform provides structured patient education modules
- ▸Optional video consultations with interdisciplinary team (skin care, nutrition, psychosocial support)
- ▸Patients engage with educational content and consultations
- ▸Improved self-management and treatment adherence lead to reduced disease severity
Who Might Benefit
Evidence fit by population:
- ▸Patients with atopic dermatitis (all ages, stratified by age and severity) recruited from 7 centers in Germany
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Results not yet available; protocol only, so noninferiority is not confirmed
- ▸Noninferiority design may not detect superiority or small differences in efficacy
- ▸Control group includes face-to-face training where available, which may reduce contrast between groups
Frequently Asked Questions
What is the ADCompanion intervention?▼
ADCompanion is a digital platform providing structured training modules and optional video consultations on skin care, nutrition, and psychosocial support, added to standard therapy for atopic dermatitis.
What is the primary outcome of the trial?▼
The primary outcome is physician-assessed disease severity measured by the Scoring Atopic Dermatitis Index (SCORAD) at 6 months.
How many participants are included?▼
The trial recruited 603 participants across 7 centers in Germany.
When will the results be available?▼
Data collection was finalized in June 2025, and final results are expected to be published in 2026.
References
- 1.Dramburg S, Hernandez Toro CJ, Telschow J, Abraham S, Almaci M, Behringer A, Christel S, Cornelius A, Feustel J, Fischer S, Gloeyer I, Günther N, Hagemeister K, Hamelmann E, Harries L, Heratizadeh A, Knappe N, Lämmel S, Moennig E, Neustädter I, Pham C, Rechtien L, Reinhold T, Schnopp C, Schorlemer C, Sollfrank L, Spies S, Stamos K, Sticherling M, Tierno P, Trentmann M, Unterweger MT, Vogelberg C, Winkler H, Worm M, Yoosefi M, Grittner U. “Remote Interdisciplinary Care for Atopic Dermatitis Using a Digital Care Concept (ADCompanion): Protocol for a Multicenter Randomized Trial..” JMIR research protocols, 2026. PMID: 42623175 DOI: 10.2196/88025